Rebecca Baker

Rebecca Baker

Auto-generated profile, based on publicly available information

Rebecca Baker

Indiana University School of Nursing, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KMKaren M. Moody
Karen M. Moody
RBRebecca A. Baker
Rebecca A. Baker
RSRuth O. Santizo
Ruth O. Santizo
IOInan Olmez
Inan Olmez
JSJeanie M. Spies
Jeanie M. Spies
ACAaron E. Carroll
Aaron E. Carroll

1 June 2017 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
KMKaren Moody
Karen Moody
BABess Abrahams
Bess Abrahams
RBRebecca Baker
Rebecca Baker
RSRuth Santizo
Ruth Santizo
DMDeepa Manwani
Deepa Manwani
ACAaron Carroll
Aaron Carroll

9 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MMMiriam B. G. Morrell
Miriam B. G. Morrell
RBRebecca Baker
Rebecca Baker
AJAbigail Johnson
Abigail Johnson
RSRuth Santizo
Ruth Santizo
DLDiane Liu
Diane Liu
Karen MoodyKaren Moody
Karen Moody

1 January 2018 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
KMKaren Moody
Karen Moody
MMMarlene McHugh
Marlene McHugh
RBRebecca Baker
Rebecca Baker
HCHillel Cohen
Hillel Cohen
PPPriya Pinto
Priya Pinto
PJPablo Joo
Pablo Joo

1 August 2020 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
Karen MoodyKaren Moody
Karen Moody
VHVerna L. Hendricks-Ferguson
Verna L. Hendricks-Ferguson
RBRebecca Baker
Rebecca Baker
SPSusan Perkins
Susan Perkins
JHJoan E. Haase
Joan E. Haase

30 March 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
AKAmelia Knopf
Amelia Knopf
MOMary A Ott
Mary A Ott
CDClaire Burke Draucker
Claire Burke Draucker
JFJ Dennis Fortenberry
J Dennis Fortenberry
DRDaniel H Reirden
Daniel H Reirden
GZGregory Zimet
Gregory Zimet
Background: Despite the high burden of new HIV infections in minor adolescents, they are often excluded from biomedical HIV prevention trials, largely owing to the ethical complexities of obtaining consent for enrollment. Researchers and ethics regulators have a duty to protect adolescents—as a special category of human subjects, they must have protection that extends beyond those afforded to all human subjects. Typically, additional protection includes parental consent for enrollment. However, parental consent can present a risk of harm for minor adolescents. Research involving minor adolescents indicate that they are unwilling to join biomedical trials for stigmatized health problems, such as HIV, when parental consent is required. This presents a significant barrier to progress in adolescent HIV prevention by creating delays in research and the translation of new scientific evidence generated in biomedical trials in adult populations. Objective: This protocol aims to examine how parental involvement in the consent process affects the acceptability of hypothetical participation in biomedical HIV prevention trials from the perspectives of minor adolescents and parents of minor adolescents. Methods: In this protocol, we use a quasi-experimental design that involves a simulated consent process for 2 different HIV prevention trials. The first trial is modeled after an open-label study of the use of tenofovir disoproxil fumarate and emtricitabine as preexposure prophylaxis for HIV. The second trial is modeled after a phase IIa trial of an injectable HIV integrase inhibitor. There are 2 groups in the study—minor adolescents aged 14 to 17 years, inclusive, and parents of minor adolescents in the same age range. The adolescent participants are randomized to 1 of 3 consent conditions with varying degrees of parental involvement. After undergoing a simulated consent process, they rate their willingness to participate (WTP) in each of the 2 trials if offered the opportunity. The primary outcome is WTP, given the consent condition. Parents undergo a similar process but are asked to rate the acceptability of each of the 3 consent conditions. The primary outcome is acceptability of the consent method for enrollment. The secondary outcomes include the following: capacity to consent among both participant groups, the prevalence of medical mistrust, and the effects of the study phase (eg, phase IIa vs the open-label study) and drug administration route (eg, oral vs injection) on WTP (adolescents) and acceptability (parents) of the consent method. Results: Enrollment began in April 2018 and ended mid-September 2019. Data are being analyzed and dissemination is expected in April 2020. Conclusions: The study will provide the needed empirical data about minor adolescents’ and parents’ perspectives on consent methods for minors. The evidence generated can be used to guide investigators and ethics regulators in the design of consent processes for biomedical HIV prevention trials. International Registered Report Identifier (IRRID): DERR1-10.2196/16509